This episode examines a bold proposal for "pharmaceutical superintelligence": a fully autonomous, AI-driven pipeline that handles everything from target identification to clinical trial planning using a single plain-language prompt. While this system could eliminate human bottlenecks and accelerate drug development, we also explore a sharp scientific critique of this vision. Critics warn that treating biology like a controllable engineering problem risks a dangerous "loss of exploration power." Because automated systems naturally favor high-confidence, efficient paths, they may prematurely prune away the unconventional or low-probability hypotheses that drive true scientific discovery. We debate the dangers of optimizing for the wrong biological proxies and discuss the necessary guardrails before AI can reliably navigate the physical complexities of human disease. Produced by Dr. Jake Chen.